Parthenon completes Bracket acquisition

 

Bracket, a specialty services provider, assists pharmaceutical companies and CROs maximise clinical data integrity and ultimately achieve greater certainty in trial outcomes with a unique range of solutions that span both eClinical and Scientific Services. With more than a decade of experience, Bracket’s team of experts has worked on more than 1,100 successful trials across 47 therapeutic areas with a particular emphasis on the central nervous system.

 

“As an independent company, Bracket will now have the autonomy, flexibility and resources to pursue our growth strategy and continue to provide best in breed technology enabled solutions for our clients,” says Catherine Spear, Bracket’s president. “We are excited to partner with Parthenon given their extensive investment experience in healthcare and deep understanding of technology’s power to advance medicine. They have a long track record of partnering with growth oriented healthcare companies like Bracket and we welcome their support as we look to grow Bracket globally through continued investment in innovative technology and cutting-edge science.”

 

David Ament, managing partner at Parthenon, says: “We are excited to have the opportunity to partner with the Bracket management team. We have been studying the clinical trials specialty services market for several years and believe Bracket offers a unique and highly compelling set of solutions to the industry.”

 

Ian Lennox has joined the Bracket board of directors as executive chairman. Lennox has invested, built and been engaged in a number of innovative companies in the clinical trial and pharmaceutical services industry, including Drug Royalty (DRI), MDS Pharma Services, Aptiv Solutions and Celerion.

 

Spear says: “Ian has a long and distinguished track record as a board member, executive, and investor in the life science industry and we welcome his insight and expertise as we embark on the next chapter of Bracket’s growth.”